Xenon Pharmaceuticals Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
7.5%projected annual EPS growth
Analyst Coverage
19analysts covering
FY Revenue (est.)
$1.2Mnext fiscal year
FY EPS (est.)
-$4.63next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Topline Data Readout for Phase 3 X-NOVA2 MDD Trial | 30 Jun 2027 |
Monitoring Framework
Key Performance Indicators
Azetukalner (XEN1101) Regulatory Progress QuarterlyTarget: NDA Submission to FDA in Q3 2026
Cash Runway and Liquidity Quarterly1.3BTarget: Support operations into 2029
Phase 3 X-NOVA2 MDD Trial Enrollment QuarterlyTarget: Topline data readout in H1 2027
Watch Items
- Azetukalner FDA NDA Filing AcceptanceTrigger: FDA acceptance of NDA filing with standard 12-month review timelineAction: Initiate full-scale commercial launch preparation and build out US sales force
- Competitor Clinical Readouts (e.g., Biohaven's opakalim or Praxis's pipeline)Trigger: Superior efficacy or safety data from competing Kv7 potassium channel openersAction: Re-evaluate market penetration models and pricing strategy for azetukalner
Research as of 19 Jun 2026